REG - Syncona Limited - Notice of Results

SynconaAnnouncement

19/05/2023 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230519:nRSS0295Aa&default-theme=true

RNS Number : 0295A  Syncona Limited  19 May 2023

 

 

 

Syncona Limited

 

Notice of Final Results

 

19 May 2023

 

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling a portfolio of global leaders in life science, will announce its
preliminary results for the period ended 31 March 2023 on Thursday 15 June
2023.

 

An in-person presentation for analysts will take place at 9.00am BST, with a
webcast available on the Company's website at https://www.synconaltd.com/
(https://www.synconaltd.com/) or via this
(https://www.lsegissuerservices.com/spark/SynconaLtd/events/44dd9457-1870-41e9-9b3d-88faeff09d72)
link. Alternatively, please contact Syncona@fticonsulting.com
(mailto:Syncona@fticonsulting.com) for details of the conference call.

 

 ENDS 

 

Enquiries

 

Syncona Ltd

 

Annabel Clay / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading healthcare
businesses, across development stage and therapeutic areas, for the benefit of
all our stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and management
teams. Our balance sheet underpins our strategy enabling us to take a
long-term view as we look to improve the lives of patients with no or poor
treatment options, build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORNKCBDCBKKAPD